My main research interest relates to how to incorporate and quantify the impact of imperfect implementation, uptake, and wider service delivery issues (such as information provision) of interventions into economic evaluations. I am particularly interested in implementation issues in precision medicine, especially regarding genetic tests and cancer. For example, my PhD explored how capacity constraints could be incorporated into economic evaluations of examples of precision medicine in breast and non-small cell lung cancer. My other work in the area of precision medicine has included an early economic evaluation of a point of care test for CYP2C19 loss of function alleles to guide prescription of clopidogrel in patients who have experienced a stroke.
In addition to my work on precision medicine, I also have an interest in the application and methods of discrete choice experiments. My work in this area has included work to elicit preferences of: members for the public for information provided alongside newborn bloodspot screening programmes; colorectal and prostate cancer survivors for healthy lifestyle and dietary advice; and patients for a hypothetical biologic calculator to guide prescribing in psoriasis.
PhD Health Economics (University of Manchester)
MSc Health Economics (University of East Anglia)
BSc (Hons) Economics (University of Kent)